Skip to main content

Advertisement

SpringerLink
Log in

Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIα for anthracycline chemotherapy in locally advanced breast cancer

  • Clinical trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose.Laboratory evidence indicates that tumor growth depends on the balance between cell proliferation and cell death, and many anticancer agents may exert their therapeutic effect by decreasing proliferation and increasing apoptosis. Additionally, clinical observations indicate that overexpression of HER-2 or topoisomerase IIα (topo IIα) may be predictors of better response to anthracyclines in breast cancer. The objective of this study was to determine if proliferation (Ki-67), apoptosis (TUNEL), and expression of HER-2 and topo IIα are affected by anthracycline treatment, and if these molecular markers predict anthracycline responsiveness.

Experimental design.Thirty-three women with primary breast tumors ≥3 cm received either doxorubicin (75 mg/m2) or epirubicin (120 mg/m2) for 4 cycles before surgery. Clinical response was evaluated after 4 cycles of treatment. Changes in molecular markers were assessed from core needle taken before treatment (D0), at 24–48 h (Dl) and on day 7 (D7) while on treatment, and from the surgical specimen excised on day 84 (D84) after the fourth cycle of chemotherapy.

Results.The overall response rate was 51% (17 of 33 patients), with a 12% complete clinical response rate (4 of 33 patients). There were trends for tumors with higher apoptosis and topo IIα at baseline (D0) to be more responsive to anthracyclines, p = 0.1 and p = 0.08, respectively. Median apoptosis increased from D0 to Dl (p = 0.06) while median Ki-67 decreased (p = 0.07). Overall, expression of HER-2 remained stable throughout the chemotherapy administration. By Day 84, topo IIα had significantly decreased from baseline in responders, while it increased in non-responders, p = 0.03.

Conclusions.In human primary breast cancer, anthracycline treatment causes an early increase in apoptosis and a decrease in proliferation. In this pilot study, higher apoptosis and topo IIαa levels in primary tumors were associated with greater responsiveness to anthracyclines, and topo IIα levels declined in responsive tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. InstitutionalAuthorNameSystemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. (1992) ArticleTitle133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists’ Collaborative Group Lancet 339 IssueID8785 71–85

    Google Scholar 

  2. N Wolmark J Wang E Mamounas J Bryant B Fisher (2001) ArticleTitlePreoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 J Natl Cancer Inst Monogr 30 96–102 Occurrence Handle11773300

    PubMed  Google Scholar 

  3. H Mouridsen T Palshof J. Patterson L Battersby (1978) ArticleTitleTamoxifen in advanced breast cancer Cancer Treat Rev 5 IssueID3 131–141 Occurrence Handle1:STN:280:CSaD1cvgtFU%3D Occurrence Handle365330

    CAS  PubMed  Google Scholar 

  4. PA Ellis IE Smith K McCarthy S Detre J Salter M Dowsett (1997) ArticleTitlePreoperative chemotherapy induces apoptosis in early breast cancer Lancet 349 IssueID9055 849 Occurrence Handle10.1016/S0140-6736(05)61752-7 Occurrence Handle1:STN:280:ByiB3snos1I%3D Occurrence Handle9121265

    Article  CAS  PubMed  Google Scholar 

  5. SM O’Reilly RS Camplejohn RD Rubens MA Richards (1992) ArticleTitleDNA flow cytometry and response to preoperative chemotherapy for primary breast cancer Eur J Cancer 28 IssueID2–3 681–683 Occurrence Handle1:STN:280:By2B2szjsFQ%3D Occurrence Handle1591092

    CAS  PubMed  Google Scholar 

  6. Y Remvikos P Vielh E Padoy B Benyahia N Voillemot H Magdelenat (1991) ArticleTitleBreast cancer proliferation measured on cytological samples: a study by flow cytometry of S-phase fractions and BrdU incorporation Br J Cancer 64 IssueID3 501–507 Occurrence Handle1:STN:280:By2D3c7islQ%3D Occurrence Handle1911191

    CAS  PubMed  Google Scholar 

  7. F Spyratos M Briffod M Tubiana-Hulin C Andrieu C Mayras C Pallud S Lasry J Rouesse (1992) ArticleTitleSequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. II. DNA flow cytometry changes during chemotherapy, tumor regression, and short-term follow-up Cancer 69 IssueID2 470–475 Occurrence Handle1:STN:280:By2D1MnpvVA%3D Occurrence Handle1728376

    CAS  PubMed  Google Scholar 

  8. S Chevillard J Lebeau P Pouillart C Toma Particlede C Beldjord B Asselain J Klijanienko A Fourquet H Magdelenat P Viehl (1997) ArticleTitleBiological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy Clin Cancer Res 3 IssueID12 Pt 1 2471–2478 Occurrence Handle1:CAS:528:DyaK1cXisFSjsg%3D%3D Occurrence Handle9815649

    CAS  PubMed  Google Scholar 

  9. S Chevillard P Pouillart C Beldjord B Asselain P Beuzeboc H Magdelenat P Vieh1 (1996) ArticleTitleSequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy Cancer 77 IssueID2 292–300 Occurrence Handle10.1002/(SICI)1097-0142(19960115)77:2<292::AID-CNCR11>3.0.CO;2-X Occurrence Handle1:STN:280:BymB38zjs1I%3D Occurrence Handle8625237

    Article  CAS  PubMed  Google Scholar 

  10. SA Rasbridge CE Gillett AM Seymour K Patel MA Richards RD Rubens RR Millis (1994) ArticleTitleThe effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma Br J Cancer 70 IssueID2 335–341 Occurrence Handle1:STN:280:ByuA3s7jt1A%3D Occurrence Handle7914426

    CAS  PubMed  Google Scholar 

  11. AD Thor DA Berry DR Budman HB Muss T Kute IC Henderson M Barcos C Cirrincione S Edgerton C Allred L Norton E Liu (1998) ArticleTitleerbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer J Natl Cancer Inst 90 IssueID18 1346–1360 Occurrence Handle10.1093/jnci/90.18.1346 Occurrence Handle1:CAS:528:DyaK1cXmtlelur4%3D Occurrence Handle9747866

    Article  CAS  PubMed  Google Scholar 

  12. S Paik J Bryant C Park B Fisher E Tan-Chiu D Hyams M Fisher D Lippman D Wickerham N Wolmar (1998) ArticleTitleerbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer J Natl Cancer Inst 90 IssueID18 1361–1370 Occurrence Handle10.1093/jnci/90.18.1361 Occurrence Handle1:CAS:528:DyaK1cXmtlelurw%3D Occurrence Handle9747867

    Article  CAS  PubMed  Google Scholar 

  13. LM Vargas-Roig FE Gago O Tello MT Martin de Civetta DR Ciocca (1999) ArticleTitlec-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy Int J Cancer 84 IssueID2 129–134 Occurrence Handle10.1002/(SICI)1097-0215(19990420)84:2<129::AID-IJC6>3.0.CO;2-4 Occurrence Handle1:CAS:528:DyaK1MXitlCrtLc%3D Occurrence Handle10096243

    Article  CAS  PubMed  Google Scholar 

  14. LM Witters SM Santala L Engle V Chinchilli A Lipton (2003) ArticleTitleDecreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells Am J Clin Oncol 26 IssueID1 50–54 Occurrence Handle10.1097/00000421-200302000-00011 Occurrence Handle1:CAS:528:DC%2BD3sXnsFCks7w%3D Occurrence Handle12576925

    Article  CAS  PubMed  Google Scholar 

  15. MD Pegram RS Finn K Arzoo M Beryt RJ Pietras DJ Slamon (1997) ArticleTitleThe effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells Oncogene 15 IssueID5 537–547 Occurrence Handle10.1038/sj.onc.1201222 Occurrence Handle1:CAS:528:DyaK2sXls1OltLc%3D Occurrence Handle9247307

    Article  CAS  PubMed  Google Scholar 

  16. LN Harris L Yang V Liotcheva S Pauli JD Iglehart OM Colvin TS Hsieh (2001) ArticleTitleInduction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy Clin Cancer Res 7 IssueID6 1497–1504 Occurrence Handle1:CAS:528:DC%2BD3MXltV2iu7w%3D Occurrence Handle11410482

    CAS  PubMed  Google Scholar 

  17. TA Jarvinen M Tanner V Rantanen M Barlund A Borg S Grenman J Isola (2000) ArticleTitleAmplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer Am J Pathol 156 IssueID3 839–847 Occurrence Handle1:CAS:528:DC%2BD3cXitVerurc%3D Occurrence Handle10702400

    CAS  PubMed  Google Scholar 

  18. DC Allred GM Clark AK Tandon R Molina DC Tormey CK Osborne KW Gilchrist EG Mansour M Abeloff L Eudey WL McGuire (1992) ArticleTitleHER-2/neu in nodenegative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma J Clin Oncol 10 599–605 Occurrence Handle1:STN:280:By2C1MzpslQ%3D Occurrence Handle1548522

    CAS  PubMed  Google Scholar 

  19. R Seshadri AS Leong K McCaul FA Firgaira V Setlur DJ Horsfall (1996) ArticleTitleRelationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis Int J Cancer 69 IssueID2 135–141 Occurrence Handle10.1002/(SICI)1097-0215(19960422)69:2<135::AID-IJC12>3.0.CO;2-8 Occurrence Handle1:STN:280:BymB3c7nt1A%3D Occurrence Handle8608982

    Article  CAS  PubMed  Google Scholar 

  20. SM Veronese C Maisano J Scibilia (1995) ArticleTitleComparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer Anticancer Res 15 IssueID6B 2717–2722 Occurrence Handle1:STN:280:BymB2s7jvFY%3D Occurrence Handle8669852

    CAS  PubMed  Google Scholar 

  21. DE Fisher (1994) ArticleTitleApoptosis in cancer therapy: crossing the threshold Cell 78 IssueID4 539–542 Occurrence Handle10.1016/0092-8674(94)90518-5 Occurrence Handle1:STN:280:ByuA2cbjsFM%3D Occurrence Handle8069905

    Article  CAS  PubMed  Google Scholar 

  22. JF Kerr AH Wyllie AR Currie (1972) ArticleTitleApoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics Br J Cancer 26 IssueID4 239–257 Occurrence Handle1:STN:280:CSyD3crgslU%3D Occurrence Handle4561027

    CAS  PubMed  Google Scholar 

  23. T Ohmori ER Podack K Nishio M Takahashi Y Miyahara Y Takeda N Kubota Y Funayama H Ogasawara T Chira (1993) ArticleTitleApoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2 Biochem Biophys Res Commun 192 IssueID1 30–36 Occurrence Handle10.1006/bbrc.1993.1377 Occurrence Handle1:CAS:528:DyaK3sXit1Gisbc%3D Occurrence Handle8476431

    Article  CAS  PubMed  Google Scholar 

  24. MI Walton D Whysong PM O’Connor D Hockenbery SJ Korsmeyer KW Kohn (1993) ArticleTitleConstitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis Cancer Res 53 IssueID8 1853–1861 Occurrence Handle1:CAS:528:DyaK3sXktVSntrk%3D Occurrence Handle8467505

    CAS  PubMed  Google Scholar 

  25. MM Compton (1992) ArticleTitleA biochemical hallmark of apoptosis: internucleosomal degradation of the genome Cancer Metastasis Rev 11 IssueID2 105–119 Occurrence Handle10.1007/BF00048058 Occurrence Handle1:CAS:528:DyaK3sXmt1agsbk%3D Occurrence Handle1327565

    Article  CAS  PubMed  Google Scholar 

  26. M Dowsett S Detre MG Ormerod PA Ellis PN Mainwaring JC Titley IE Smith (1998) ArticleTitleAnalysis and sorting of apoptotic cells from fine-needle aspirates of excised human primary breast carcinomas Cytometry 32 IssueID4 291–300 Occurrence Handle10.1002/(SICI)1097-0320(19980801)32:4<291::AID-CYTO6>3.0.CO;2-L Occurrence Handle1:STN:280:DyaK1czmsFWhug%3D%3D Occurrence Handle9701398

    Article  CAS  PubMed  Google Scholar 

  27. FW Symmans (2001) ArticleTitleBreast cancer response to paclitaxel in vivo Drug Resist Updat 4 IssueID5 297–302 Occurrence Handle10.1054/drup.2001.0218 Occurrence Handle1:CAS:528:DC%2BD38Xkt1Sjs7c%3D Occurrence Handle11991683

    Article  CAS  PubMed  Google Scholar 

  28. J Chang M Ormerod TJ Powles DC Alfred SE Ashley M Dowsett (2000) ArticleTitleApoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma Cancer 89 IssueID11 2145–2152 Occurrence Handle10.1002/1097-0142(20001201)89:11<2145::AID-CNCR1>3.0.CO;2-S Occurrence Handle1:STN:280:DC%2BD3M%2FosF2rsw%3D%3D Occurrence Handle11147583

    Article  CAS  PubMed  Google Scholar 

  29. J Chang TJ Powles DC Alfred SE Ashley A Makris RK Gregory Osborne CK M Dowsett (2000) ArticleTitlePrediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients Clin Cancer Res 6 IssueID2 616–621 Occurrence Handle1:CAS:528:DC%2BD3cXhs1akt74%3D Occurrence Handle10690547

    CAS  PubMed  Google Scholar 

  30. J Gerdes RJ Lelle H Pickartz W Heidenreich R Schwarting L Kurtsiefer G Stauch H Stein (1986) ArticleTitleGrowth fractions in breast cancers determined in situ with monoclonal antibody Ki-67 J Clin Pathol 39 IssueID9 977–980 Occurrence Handle1:STN:280:BiiD3cbht1E%3D Occurrence Handle3020096

    CAS  PubMed  Google Scholar 

  31. J Chang TJ Powles DC Alfred SE Ashley GM Clark A Makris L Assersohn RK Gregory CK Osborne M Dowsett (1999) ArticleTitleBiologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer J Clin Oncol 17 IssueID10 3058–3063 Occurrence Handle1:STN:280:DyaK1MvjvVWksg%3D%3D Occurrence Handle10506600

    CAS  PubMed  Google Scholar 

  32. HB Muss AD Thor DA Berry T Kute ET Liu F Koerner CT Cirrincione DR Budman WC Wood M Barcos (1994) ArticleTitlec-erbB-2 expression and response to adjuvant therapy in women with node- positive early breast cancer N Engl J Med 330 IssueID18 1260–1266 Occurrence Handle10.1056/NEJM199405053301802 Occurrence Handle1:STN:280:ByuC1MrjsVc%3D Occurrence Handle7908410

    Article  CAS  PubMed  Google Scholar 

  33. A Vincent-Salomon M Carton P Freneaux T Palangie P Beuzeboc E Mouret P Cremoux Particlede O. Coue B Zafrani A Nicolas K Clough A Fourquet P Pouillart X Sastre-Garau (2000) ArticleTitleERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy Eur J Cancer 36 IssueID5 586–591 Occurrence Handle10.1016/S0959-8049(99)00339-1 Occurrence Handle1:CAS:528:DC%2BD3cXitVSnsL0%3D Occurrence Handle10738122

    Article  CAS  PubMed  Google Scholar 

  34. JS Coon E Marcus S Gupta-Burt S Seelig K Jacobson S Chen V Renta G Fronda HD Preisler (2002) ArticleTitleAmplification and overexpression of topoisomerase II alpha predict response to anthracycline-based therapy in locally advanced breast cancer Clin Cancer Res 8 IssueID4 1061–1067 Occurrence Handle1:CAS:528:DC%2BD38XjsF2ltr8%3D Occurrence Handle11948114

    CAS  PubMed  Google Scholar 

  35. AM Dingeinans MA Witlox RA Stallaert P Valk Particlevan der PE Postmus G Giaccone (1999) ArticleTitleExpression of DNA topoisotnerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer Clin Cancer Res 5 IssueID8 2048–2058 Occurrence Handle10473085

    PubMed  Google Scholar 

  36. E Klumper G Giaccone R Pieters G Broekema J Ark-Otte Particlevan ER Wering Particlevan GJ Kaspers AJ Veerman (1995) ArticleTitleTopoisomerase II alpha gene expression in childhood acute lymphoblastic leukemia Leukemia 9 IssueID10 1653–1660 Occurrence Handle1:STN:280:BymD3Mzps1Y%3D Occurrence Handle7564505

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Baylor College of Medicine, Houston, Texas, USA

    G. Arpino, H. Weiss, D. C. Allred, R. Elledge & S. K. Mohsin

  2. Institute of Experimental Medicine and Biology of Cuyo, Mendoza, Argentina

    D. R. Ciocca & L. Vargas-Roig

  3. Hospital L. Lagomaggiore, Medical School, University of Cuyo, Mendoza, Argentina

    P. Daguerre & M. Leuzzi

  4. Hospital Italiano, Medical School, University of Cuyo, Mendoza, Argentina

    F. Gago

  5. Breast Care Center, 6550 Fannin Street, 7th Floor, Suite 701, Houston, TX , USA, 77030

    R. Elledge

Authors
  1. G. Arpino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. R. Ciocca
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Weiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. C. Allred
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Daguerre
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L. Vargas-Roig
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Leuzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F. Gago
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R. Elledge
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S. K. Mohsin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Elledge.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arpino, G., Ciocca, D.R., Weiss, H. et al. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIα for anthracycline chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat 92, 69–75 (2005). https://doi.org/10.1007/s10549-005-1721-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-005-1721-9

Key words

Search

Navigation